This page was translated automatically from Turkish. Read the original

Bu sayfa, 26. Dünya Psikiyatri Kongresi'nde sunulan çalışmanın yapay zekâ desteğiyle hazırlanmış Türkçe özetidir. Çalışmanın sahibi sunan yazarlardır; atıf için orijinal kaynağa başvurun.

SO393

Cognitive outcomes of antidepressant use in patients with cancer: a systematic review

COGNITIVE OUTCOMES OF ANTIDEPRESSANT USE IN PATIENTS WITH CANCER: A SYSTEMATIC REVIEW

In this review of seven studies, evidence for the short-term beneficial effects of antidepressants on cognitive function was more consistent than evidence for their long-term effects.

The aim of the study was to evaluate the effects of antidepressant medications on cognitive function in patients with cancer. This systematic review, conducted using PubMed in accordance with PRISMA guidelines, included studies reporting cognitive outcomes in domains such as attention, memory, executive function, processing speed, working memory, semantic fluency, and visuospatial skills in oncology populations receiving antidepressant treatment. Risk of bias was assessed using standardized tools. According to the flow diagram, 476 records were screened and 469 reports were assessed for eligibility; the reasons for exclusion were reported as review (n = 174), irrelevant (n = 158), in vivo (n = 59), outside the scope (n = 48), case report (n = 21), in vitro (n = 6), and opinion piece (n = 3), with seven studies meeting the inclusion criteria (n = 7). Studies examining short-term antidepressant use reported potential cognitive benefits associated with sertraline, vortioxetine, and low-dose esketamine, particularly with respect to executive function and perioperative neurocognitive disorders; these findings were accompanied by improvements in depressive symptoms. Findings from studies focusing on long-term outcomes were heterogeneous. Overall, the available evidence is more consistent in supporting the short-term benefits of antidepressants on cognitive function than their long-term effects; however, the evidence base is limited by the small number of studies in this field. Clinically, this suggests that cognitive outcomes may be considered when selecting antidepressants for patients with cancer, but that no strong recommendation can be made regarding long-term cognitive effects.

Tüm WCP 2026 özetleri